Increased doses of the corticosteroid fluticasone propionate safely and effectively induce remission in many people with eosinophilic esophagitis (EoE). EoE is a chronic inflammatory disease of the esophagus characterized by high levels of white blood cells called eosinophils.
However, some trial participants did not respond to fluticasone even after six months of high-dose treatments, providing evidence that certain people with EoE are steroid-resistant. By analyzing gene expression—the degree to which certain genes are turned on or off—in esophageal tissues, the scientists identified a cluster of genes that may help predict steroid responsiveness. The study, led by Marc Rothenberg, M.D., Ph.D., of Cincinnati Children's Hospital Medical Center and the University of Cincinnati, was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Oesophageal atresia
Oesophageal atresia is blockage in the oesophagus (food pipe). It is often associated with an abnormal connection between the oesophagus and trachea (wind pipe) below the level of blockage.
EoE affects an estimated 1 in 2,500 people. Symptoms vary, and may include trouble swallowing and abdominal pain. Based on previous research by Dr. Rothenberg and others, physicians typically use oral fluticasone off-label to treat patients with EoE, but studies have shown that some patients do not respond to 880-microgram daily doses of the drug. In the current study, researchers evaluated the effectiveness of a higher dose in adults and children with EoE. For three months, 28 participants swallowed 1760 micrograms of fluticasone each day, while 14 received placebo. At the end of the three-month period, 65 percent of participants who took the drug were in complete remission, based on the near absence of eosinophils in their esophageal tissues, compared to none who took placebo. Those in remission were switched to 880 micrograms of daily fluticasone for an additional three months, and 93 percent remained in complete or partial remission. Participants who did not respond to fluticasone during the first three months received 1760-microgram doses for three more months, but remained largely unresponsive to the drug. The findings suggest that approximately 25 percent of people with EoE do not respond to steroid treatment.
Source: Eurekalert
New Research Implicates Esophageal Function in Life-Threatening Experiences in Infants
Research has shown that nearly 1 percent of all emergency room visits are prompted by near-death experiences in infants.
 Physical Activity May Cut Esophageal Cancer RiskA new study finds that physical activity is associated with a reduced risk of esophageal cancer. | Advertisement
|
Promising Biomarker for Esophageal Cancer With Current Research Findings
Improvement in screening for esophageal cancer and its precursor, Barrett's esophagus, is possible with a research finding of a new biomarker.
Recommended Reading
Latest Drug News
